ZOSTAVAX Rx

Select the drug indication to add to your list

ZOSTAVAX

Vaccines
Only 4 drugs may be compared at once

Generic Name and Formulations:

Varicella zoster vaccine, live, attenuated; minimum of 19,400 PFU/0.65mL dose; pwd for SC inj after reconstitution; contains porcine gelatin, neomycin and bovine serum (trace); preservative-free.

Select therapeutic use:

Indications for ZOSTAVAX:

Prevention of herpes zoster (shingles) in adults ≥50 years of age.

Adult:

<50yrs: not recommended. ≥50yrs: one 0.65mL dose by SC inj once in upper arm. Administer immediately upon reconstitution.

Children:

Not recommended.

Contraindications:

Immunodeficiency (eg, HIV, leukemia, lymphoma, bone marrow or lymphatic cancer, immunosuppressive therapy). Pregnancy (during and 3 months after vaccination).

Warnings/Precautions:

Not for treating zoster or postherpetic neuralgia. Not for preventing primary varicella infection. Defer in untreated tuberculosis. Consider deferral in acute illness. Have epinephrine inj (1:1000) available. May not protect 100% of recipients. Virus transmission may occur between recipients and susceptible contacts. Nursing mothers.

Interactions:

See Contraindications. Immunosuppressants may cause disseminated disease. Consider administration of Zostavax and Pneumovax 23 vaccines separated by ≥4 weeks.

Adverse Reactions:

Inj site reactions (eg, erythema, pain, swelling, pruritus), headache, cardiovascular diseases (eg, CHF, pulmonary edema).

Note:

To register pregnant patients exposed to Zostavax: (800) 986-8999. To report adverse events to VAERS: (800) 822-7967.

Generic Availability:

NO

How Supplied:

Single-dose vials—1, 10 (w. diluent)

ZOSTAVAX 0.65ml vials (Qty:1)

appx. price $206.00